DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125486/S-013

SUPPLEMENT APPROVAL

Genentech, Inc.
Attention: Thomas Haberberger, PhD
Regulatory Program Management
1 DNA Way MS# 241B
South San Francisco, CA 94080-4990

Dear Dr. Haberberger:

Please refer to your Supplemental Biologics License Application (sBLA), dated August 28, 2015, received August 28, 2015, and your amendments, submitted under section 351(a) of the Public Health Service Act for Gazyva® (obinutuzumab) injection, 1000 mg/40 mL (25 mg/mL).

This Prior Approval supplemental biologics application provides for a new indication, which is Gazyva®, in combination with bendamustine followed by Gazyva® monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. The new indication is based on efficacy and safety data from the primary analysis of Study GAO4753g/GO01297 (GADOLIN), which evaluated obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy, compared with bendamustine alone in patients with indolent non-Hodgkin lymphoma (iNHL) who did not respond to or progressed during or after treatment with rituximab or a rituximab-containing regimen.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "*SPL Standard for Content of Labeling Technical Qs and As*" at

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this biologic product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

PMC #3048-1 Submit the final study report for the stage 2 (GClb versus RClb) of the BO21004/CLL11 trial entitled, "*An Open-label, Multi-center, Three Arm Randomized, Phase 3 Study to Compare the Efficacy and Safety of RO5072759 + Chlorambucil (GClb), Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients with Comorbidities*" which shall include overall survival results at the end of the study. The final report will provide summary analysis and primary data. Accrual to this trial has been completed.

The timetable you submitted on February 16, 2016, states that you will conduct this study according to the following schedule:

Study Completion:	07/2020
Final Report Submission:	07/2021

PMC #3048-2 Submit the final study report for the clinical trial GAO4753g (GADOLIN) entitled, "*An open-label, multicenter, randomized, phase 3 study to investigate the efficacy and safety of bendamustine compared with bendamustine+RO5072759 (GA101) in patients with rituximab-refractory indolent non-Hodgkin's lymphoma*" which shall include the overall survival results at the planned final

analysis after 226 deaths. The final report will provide summary analysis and primary data. Accrual to this trial has been completed.

The timetable you submitted on February 16, 2016, states that you will conduct this study according to the following schedule:

Study Completion:	12/2019
Final Report Submission:	12/2020

Submit all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected study completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies and trials, number of patients entered into each study or trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled "**Postmarketing Commitment Protocol," "Postmarketing Commitment Final Report," or "Postmarketing Commitment Correspondence**."

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Beatrice Kallungal, Regulatory Project Manager, at (301) 796-9304.

Sincerely,

{See appended electronic signature page}

Edvardas Kaminskas, MD
Deputy Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

EDVARDAS KAMINSKAS
02/26/2016